Erratum to: Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model

El-Shemi, Adel Galal; Ashshi, Ahmad Mohammed; Na, Youjin; Li, Yan; BaSalamah, Mohammad A.; Al-Allaf, Faisal A.; Oh, Eonju; Jung, Bo‐Kyeong; Yun, Chae‐Ok

doi:10.1186/s13046-016-0365-4

Cited by 8 publications

(1 citation statement)

References 1 publication

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their study showed that a combination of two anti-tumor genes (IL-24 with TRAIL) may be a promising strategy for gene-viro therapy, which exhibits a synergistic anti-tumor effect (98). Furthermore, the combination therapy of Ad-ΔB/IL-12 with Ad-ΔB/TRAIL exhibits an enhanced anti-tumor immune response due to IL-12 being able to upregulate the TRAIL expression of NK cells, resulting in IFN-γ-dependent NK cell-related tumor metastasis inhibition (45, 100). Co-therapy with IL-12 and TRAIN complements TRAIL mono therapy poor pharmacokinetic property and induce HCC cells sensitivity to TRAIL's apoptotic effect (101).…”

Section: Modulation Of the Host Immune Response Triggered By Oncolytimentioning

confidence: 99%

Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC

et al. 2019

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most frequent cancers worldwide, particularly in China. Despite the development of HCC treatment strategies, the survival rate remains unpleasant. Gene-targeted oncolytic viral therapy (GTOVT) is an emerging treatment modality—a kind of cancer-targeted therapy—which creates viral vectors armed with anti-cancer genes. The adenovirus is a promising agent for GAOVT due to its many advantages. In spite of the oncolytic adenovirus itself, the host immune response is the determining factor for the anti-cancer efficacy. In this review, we have summarized recent developments in oncolytic adenovirus engineering and the development of novel therapeutic genes utilized in HCC treatment. Furthermore, the diversified roles the immune response plays in oncolytic adenovirus therapy and recent attempts to modulate immune responses to enhance the anti-cancer efficacy of oncolytic adenovirus have been discussed.

show abstract

Section: Modulation Of the Host Immune Response Triggered By Oncolytimentioning

confidence: 99%

Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC

et al. 2019

View full text Add to dashboard Cite

show abstract

Systematic review of the roles of interleukins in hepatocellular carcinoma

Xiao

2020

Clinica Chimica Acta

View full text Add to dashboard Cite

Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma

Yoo

Badrinath

Woo

et al. 2017

Mediators of Inflammation

View full text Add to dashboard Cite

Hepatocellular carcinoma is highly refractory cancer which is resistant to conventional chemotherapy and radiotherapy, carrying a dismal prognosis. Although many anticancer drugs have been developed for treating HCC, sorafenib is the only effective treatment, but it only prolongs survival duration for about 3 months. Recently, oncolytic virotherapy has shown promising results in treating HCCs and the effects can be more enhanced by adopting immune modulatory molecules. This review discusses the current status of treating HCC and the effective strategy of oncolytic virus-based immunotherapy for the treatment of HCCs.

show abstract

Erratum to: Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model

Cited by 8 publications

References 1 publication

Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC

Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC

Systematic review of the roles of interleukins in hepatocellular carcinoma

Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma

Contact Info

Product

Resources

About